View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
November 4, 2020

Coronavirus company news summary – J&J given permission to resume clinical trial in Brazil – Mexico signs deal with CanSino for vaccine trial

By Allie Nawrat

4 November 2020 

Anvisa, the Brazilian health regulator, has authorised Johnson & Johnson (J&J) to resume its clinical trial of its experimental Covid-19 vaccine. The vaccine candidate is one of four candidates being tested for efficacy and safety in Brazil. J&J’s trial had been suspended due to an unexplained illness in a participant in a Phase III study in October.

Humanigen announced that is has implemented its first licensing agreement with Telcon RF Pharmaceutical and KPM Tech to provide development and commercialisation rights of its drug candidate Lenzilumab to treat Covid-19 in South Korea and the Philippines.

The Kingdom of Bahrain has authorised emergency use of Covid-19 vaccine for frontline healthcare staff who come in direct contact with positive coronavirus patients. HE Faeqa Al Saleh, the Minister of Health, emphasised that the vaccines will be administered to healthcare workers with immediate effect, thereby protecting frontline workers from the risks of exposure to the disease.

Foreign minister Marcelo Ebrard stated that Mexico had received the first doses of a Covid-19 vaccine candidate from CanSino Biologics. The doses are intended for a late-stage trial to be conducted in between 10,000 and 15,000 volunteers. The country has collaborated with WHO-backed COVAX and other companies to attempt to vaccinate most of the country by the end of 2021.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology